



Robert Greene Sterne
Jorge A. Goldstein
David K.S. Cornwell
Robert W. Esmond
Tracy Gene G. Durkin
Michele A. Cimbalia
Michael B. Ray
Robert E. Sokohl
Eric K. Steffe
Michael Q. Lee
John M. Covert
Robert C. Millonig
Donald J. Featherstone
Timothy J. Shea, Jr.
Michael V. Messinger
Judith U. Kim
Jeffrey T. Helvey
Eldora L. Ellison
Donald R. Banowit

Peter A. Jackman
Brian J. Del Buono
Mark Fox Evans
Vincent L. Capuano
Elizabeth J. Haasies
Michael D. Specht
Kevin W. McCabe
Glenn J. Perry
Edward W. Yee
Grant E. Reed
Virgil Lee Beaton
Theodore A. Wood
Joseph S. Ostroff
Jason D. Eisenberg
Tracy L. Muller
Jon E. Wright
LuAnne M. DeSantis
Ann E. Summerfield
Helene C. Carlson

Cynthia M. Bouchez
Timothy A. Doyle
Gaby L. Longworth
Lori A. Gordon
Laura A. Vogel
Bryan S. Wade
Bashir M.S. Ali
Shannon A. Carroll
Anbar F. Khal
Michelle K. Holoubek
Marsha A. Rose
Scott A. Schaller
Lei Zhou
Young Tang
Christopher J. Walsh
W. Blake Coblenz
James J. Pohl
John T. Haran
Mark W. Rygiel

Michael R. Malek*
Carla Ji-Eun Kim
Doyle A. Siever*
Ulrike Winkler
Bryan L. Skelton*
Paul A. Calvo
Robert A. Schwartzman
C. Matthew Rozier
Alexandra K. Pechhold
Registered Patent Agents*
Karen R. Markowicz
Matthew J. Dowd
Katrina Yujian Pei Quach
Julie A. Heider
Mita Mukherjee

Scott M. Woodhouse
Peter A. Socarras
Jeffrey K. Mills
Danielle L. Letting
Lori Brandes
Steven C. Oppenheimer
Aaron S. Lukas
Gaurav Asthana
Of Counsel
Edward J. Kessler
Kenneth C. Bass III
Marvin C. Guthrie
Christopher P. Wrist
*Admitted only in Maryland
*Admitted only in Virginia
•Practice Limited to Federal Agencies

November 2, 2007

WRITER'S DIRECT NUMBER:
(202) 772-8547
INTERNET ADDRESS:
VCAPUANO@SKGF.COM

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

Mail Stop PCT

Re: U.S. Utility Patent Application
Application No. 10/580,481 (*U.S. Nat'l Phase of Int'l Appl. No.*
PCT/US04/40284); Int'l Filing Date: December 2, 2004
For: **Insecticidal N-(Heteroarylalkyl) Alkanediamine Derivatives**
Inventors: ROUSH *et al.*
Our Ref: 2400.11400002/VLC/L-Z

Sir:

Transmitted herewith for appropriate action are the following documents:

1. Information Disclosure Statement;
2. 1 page of PTO/SB/08A form listing 3 US patent and 3 foreign patent documents;
3. 1 page of PTO/SB/08B form listing 3 NPL documents; and
4. Copies of 3 foreign patent and 3 NPL documents (FP1 to FP3 and NPL1 to NPL3).

The above listed documents are filed electronically through EFS-Web.

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.

For *Lei Zhou (48,291)*
Vincent L. Capuano
Attorney for Applicants
Registration No. 42,385

VLC/L-Z/ecw
Enclosures

728997_1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

ROUSH *et al.*

Appl. No.: 10/580,481 (*U.S. Nat'l Phase
of Int'l Appl. No.
PCT/US04/40284*)

Int'l Filing Date: December 2, 2004

For: **Insecticidal N-
(Heteroarylalkyl)Alkanediamine
Derivatives**

Confirmation No.: 4205

Art Unit: *To Be Assigned*

Examiner: *To Be Assigned*

Atty. Docket: 2400.1140002/VLC/L-Z

Information Disclosure Statement Under 37 C.F.R. §1.97(b)

Mail Stop PCT

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

Sir:

Listed on accompanying IDS Forms, PTO/SB/08A and PTO/SB/08B, are documents that may be considered material to the examination of this application, in compliance with the duty of disclosure requirements of 37 C.F.R. §§ 1.56, 1.97 and 1.98.

Copies of documents **FP1** to **FP3** and **NPL1** to **NPL3** are submitted. However, in accordance with 37 C.F.R. § 1.98(a)(2), copies of U.S. patents and patent application publications, **US1** to **US3**, cited on the attached IDS Form, PTO/SB/08A, are not submitted.

In accordance with 37 C.F.R. § 1.98(a)(3), Applicants' undersigned representative submits the following discussion of the relevance of the non-English language documents **FP1** and **FP3** cited on Form PTO/SB/08A:

Document **FP1**, EP 0 254 859 A2, is in the German language. An English language equivalent of document FP1 is cited as document **US1**.

Document **FP3**, JP 8-269035 A, is in the Japanese language. An English language abstract of document FP2 is cited as document **NPL3** and submitted herewith.

The Examiner's attention is directed to the following co-pending U.S. Patent Applications, which are directed to related technical subject matter:

Application No. 11/698,993, inventors Chiarello *et al.*, filed January 29, 2007; not published; and

Application No. 11/577,664, inventors Roush *et al.*, filed April 20, 2007; and not published.

The identification of these U.S. Patent Applications is not to be construed as a waiver of secrecy as to those applications now or upon issuance of the present application as a patent. The Examiner is respectfully requested to consider the cited applications and the art cited therein during examination.

Where the publication date of a listed document does not provide a month of publication, the year of publication of the listed document is sufficiently earlier than the effective U.S. filing date and any foreign priority date so that the month of publication is not in issue. Applicants have listed publication dates on the attached IDS Forms based on information presently available to the undersigned. However, the listed publication dates should not be construed as an admission that the information was actually published on the date indicated.

Applicants reserve the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist. The Examiner is specifically requested not to rely solely on the material submitted herewith.

This Information Disclosure Statement is being filed before the mailing date of a first Office Action on the merits. No statement or fee is required.

It is respectfully requested that the Examiner initial and return a copy of the enclosed IDS Forms, and indicate in the official file wrapper of this patent application that the documents have been considered.

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.

For *Leizhou (48,291)*
Vincent L. Capuano
Attorney for Applicants
Registration No. 42,385

Date: Nov. 2, 2007

1100 New York Avenue, N.W.
Washington, D.C. 20005-3934
(202) 371-2600

728915_1